StudyFinder
ACTIV-6: COVID-19 Study of Repurposed Medications
Recruiting
All
30 Years and over
Inclusion Criteria:
• Completed Informed Consent
• Age ≥ 30 years old
• Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction (PCR) or antigen test collected within 10 days of screening
• Two or more current symptoms of acute infection for ≤7 days. Symptoms include the following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell
Exclusion Criteria:
• Prior diagnosis of COVID-19 infection (> 10 days from screening)
• Current or recent (within 10 days of screening) hospitalization
• Known allergy/sensitivity or any hypersensitivity to components of the study drug or placebo
• Known contraindication(s) to study drug including prohibited concomitant medications
Drug: Ivermectin, Drug: Fluvoxamine, Drug: Fluticasone, Other: Placebo
Covid19
SARS-CoV-2, COVID-19, ivermectin, Placebo, Duke University Health System, Outcomes, Duke Clinical Research Institute, fluticasone, fluvoxamine, ACTIV 6, ACTIV
Manju Nayar - nayar008@umn.edu
Barkha Patel - pate1125@umn.edu
Barkha Patel - pate1125@umn.edu
Phase 3
NCT04885530
See this study on ClinicalTrials.gov